相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease
Lailiang Qu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2
Zhihao Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma
Yalin Tu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA
Cheng Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders
Stefano Tomassi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition
Sergey Karakashev et al.
CANCER CELL (2020)
Discovery of a first-in-class EZH2 selective degrader
Anqi Ma et al.
NATURE CHEMICAL BIOLOGY (2020)
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex
Jessie Hao-Ru Hsu et al.
CELL CHEMICAL BIOLOGY (2020)
Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader
Frances Potjewyd et al.
CELL CHEMICAL BIOLOGY (2020)
Breast Cancer Treatment A Review
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro et al.
CANCER DISCOVERY (2019)
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
Pei-Pei Kung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Ian Churcher
JOURNAL OF MEDICINAL CHEMISTRY (2018)
CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity
Sergey Karakashev et al.
NATURE COMMUNICATIONS (2018)
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
Jung Kim et al.
CELL REPORTS (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Waste disposal-An attractive strategy for cancer therapy
Jemilat Salami et al.
SCIENCE (2017)
Small-Molecule Modulation of Protein Homeostasis
George M. Burslem et al.
CHEMICAL REVIEWS (2017)
Targeting EZH2 in cancer therapy
Makoto Yamagishi et al.
CURRENT OPINION IN ONCOLOGY (2017)
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
Rishi G. Vaswani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Targeting EZH2 in cancer
Kimberly H. Kim et al.
NATURE MEDICINE (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kimberly H. Kim et al.
NATURE MEDICINE (2015)
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
Edward Curry et al.
CLINICAL EPIGENETICS (2015)
An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
Kyle D. Konze et al.
ACS CHEMICAL BIOLOGY (2013)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network
Nancy U. Lin et al.
CANCER (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Sarah K. Knutson et al.
NATURE CHEMICAL BIOLOGY (2012)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu et al.
SCIENCE (2012)
The Polycomb complex PRC2 and its mark in life
Raphael Margueron et al.
NATURE (2011)
Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms
Raphael Margueron et al.
MOLECULAR CELL (2008)
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein
A Kuzmichev et al.
GENES & DEVELOPMENT (2002)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites
B Czermin et al.
CELL (2002)
分享论文
